$2.60
+0.10(4.00%)
Mkt Cap $8M
$2.50
$13.85
52-Week Range
At a Glance
AI-generatedCellectar Biosciences, Inc.
8-K
Cellectar Biosciences, Inc. announced financial results for the year ended December 31, 2025, reporting a net loss of $21.8 million or $8.35 per basic and diluted share, compared to $44.6 million or $36.52 per basic share in 2024. Cash and cash equivalents stood at $13.2 million as of December 31, 2025, adequate to fund basic operations into Q3 2026, alongside pipeline updates including planned CMA submission for iopofosine I 131 in Q3 2026.$8M
Market Cap
—
Revenue
-$16M
Net Income
Employees11
Fundamentals
How The Business Makes Money
Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study in patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia and B-cell malignancies; Phase 2B clinical study in r/r multiple myeloma (MM) patients; and Phase I study for various pediatric cancers, r/r head and neck cancers, and R/R MM. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative PDC programs with Avicenna Oncology GMBH to develop CLR 2000 Series; Orano Med to develop CLR 12120 Series; IntoCell Inc; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.
Industry Biotechnology
Activity
Analyst View
Company Profile
CIK0001279704
ISINUS15117F8804
CUSIP15117F880
Phone608 441 8120
Address100 Campus Drive, Florham Park, NJ, 07932, US
SEC EDGAR